Gilead’s (GILD) remdesivir study in China for mild-moderate Covid-19 patients has just been suspended due to poor enrollment. The news comes as the pandemic continues to wane in China, and follows the recently announced termination of the study for severe Covid-19 patients for similar reasons.According to reports, the mild-moderate study had planned to enroll 308 patients from Wuhan- but it remains unclear exactly how many enrolled to date. The stock is currently down 3% in today’s trading, but is still up 16% year-to-date.For RBC Capital analyst Brian Abrahams this latest update is a worrying sign of the drug’s efficacy. He …read more
Source:: Yahoo Finance
